The fact that P245 treatment during tumour remission inhibits tumour recurrence suggests that CD44+ cells play a direct role in the tumour recurrence, providing an interesting target and a useful model to finalise breast cancer therapies associations. This evidence concerns the gene CD44 and breast cancer.